Butamisole - Misplaced Pages

This is an old revision of this page, as edited by Graeme Bartlett (talk | contribs) at 07:55, 26 December 2024 (more ids). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Revision as of 07:55, 26 December 2024 by Graeme Bartlett (talk | contribs) (more ids)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound

Butamisole
Identifiers

IUPAC name 2-Methyl-N-thiazol-6-yl)phenyl]propanamide
CAS Number	54496-44-5
PubChem CID	166572
ChemSpider	145767
ChEMBL	ChEMBL2110807
CompTox Dashboard (EPA)	DTXSID8057770
Chemical and physical data
Formula	C₁₅H₁₉N₃OS
Molar mass	289.40 g·mol
3D model (JSmol)	Interactive image
SMILES CC(C)C(=O)NC1=CC=CC(=C1)C2CN3CCSC3=N2
InChI InChI=1S/C15H19N3OS/c1-10(2)14(19)16-12-5-3-4-11(8-12)13-9-18-6-7-20-15(18)17-13/h3-5,8,10,13H,6-7,9H2,1-2H3,(H,16,19) Key:YWDWYOALXURQPZ-UHFFFAOYSA-N

Butamisole is a pharmaceutical drug used in veterinary medicine. It is an anthelmintic of the imidazothiazole class. In dogs it is used for the treatment of infections with whipworms such as Trichuris vulpis and with hookworm such as Ancylostoma caninum. It acts as a nicotinic acetylcholine receptor agonist that causes sustained muscle contraction in the parasite followed by depolarizing neuromuscular blockade which leads to paralysis.

References

B. T. Alford, G. T. Wang, T. R. Garces, R. B. Dougherty, R. E. Bradley (1979). "The efficacy and safety of injectable butamisole in dogs". Veterinary Medicine & Small Animal Clinician. 74 (4): 487–495.{{cite journal}}: CS1 maint: multiple names: authors list (link)
Martin, R.J. (1997). "Modes of action of anthelmintic drugs". The Veterinary Journal. 154 (1): 11–34. doi:10.1016/S1090-0233(05)80005-X. PMID 9265850.
^ "Butamisole". Inxight Drugs. National Center for Advancing Translational Sciences.

This veterinary medicine–related article is a stub. You can help Misplaced Pages by expanding it.